NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners<
24 Sep 2018

Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners

Ysios Capital has appointed Guillem Laporta as Principal and two new Venture Partners: Lance Berman and Claudia D’Augusta.
18 Sep 2018

BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

BioClin Therapeutics, Inc., today announced the appointment of Scott Myers as Chief Executive Officer, and Julie Eastland as Chief Financial Officer and Chief Business Officer. Mr. Myers will also continue in his role as company Chairman.
05 Sep 2018

Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE)

Minoryx Therapeutics, today announces the dosing of its first US patient as part of its ongoing phase 2/3 clinical trial of MIN-102 for the treatment of adrenomyeloneuropathy.
Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma<
04 Sep 2018

Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma

Company prepares to initiate late stage clinical development for its flagship drug in choroidal melanoma next year.
06 Aug 2018

Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis

Laboratoris Sanifit S.L., today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
31 Jul 2018

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period

Takeda Pharmaceutical Company Limited and TiGenix NV today announced that Takeda has acquired all outstanding ordinary shares and warrants of TiGenix following the expiration of the squeeze-out period.
Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting<
25 Jul 2018

Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting

Interim data presented at ASRS show that in an expanded set of subjects AU-011 continues to be well-tolerated with no related serious adverse events.
10 Jul 2018

CorWave’s next-generation LVAD, Neptune, receives funding

The CALYPSO Research and Development (R&D) program, with a total budget of 25 million euros over 4 years, will be partially financed with 14 million euros support from the Program d'Investissements d'Avenir (Future Investments Program), managed by the Secrétariat Général pour l’Investissement (General Secretariat for Investment – SGPI) and operated by Bpifrance.
27 Jun 2018

BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors

BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of   Board of Directors.
Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma<
17 Jun 2018

Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma

AU-011 is an investigational, first-in-class targeted therapy in development for the treatment of primary choroidal melanoma.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.